Zobrazeno 1 - 10
of 160
pro vyhledávání: '"David E Gyorki"'
Autor:
Yun Song, John F Thompson, Frances A Collichio, Tasha Hughes, John Vetto, Dale Han, Jonathan Zager, Zeynep Eroglu, Jennifer Downs, David E Gyorki, Nikhil I Khushalani, Alexander van Akkooi, Georgia Beasley, Lisa Kottschade, Hidde M Kroon, Ann Lee, Norma E Farrow, Giorgos Karakousis, Michael Lowe, Avinash Sharma, Kristy K Broman, Amanda Nijhuis, Tina J Hieken, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Lesly Dossett, Russell S Berman, Emma Stahlie, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, David W Ollila, Roger Olofsson Bagge, Jan Mattsson, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial
Externí odkaz:
https://doaj.org/article/5e2609c2e5e44274aabf900f1ff2c1c7
Autor:
Shahneen Sandhu, David E Gyorki, Richard A Scolyer, George Au-Yeung, Grant A McArthur, Minyu Wang, Georgina Long, Angela Pizzolla, Paul Joseph Neeson, Soroor Zadeh, Kevin Thia, James S Wilmott, Miles C Andrews, Ali Weppler, Joseph A Trapani, Melissa J Davis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/a361f758191942e486d27c60762fc49d
Autor:
Michael Henderson, Frances Rapport, Rachael L Morton, John F Thompson, Andrea L Smith, Anne E Cust, Graham J Mann, Caroline G Watts, David E Gyorki, Angela M Hong, John W Kelly, Victoria J Mar, Robyn PM Saw, Richard A Scolyer, Andrew J Spillane
Publikováno v:
BMJ Open, Vol 10, Iss 2 (2020)
IntroductionSentinel lymph node biopsy (SLNB) is a diagnostic procedure developed in the 1990s. It is currently used to stage patients with primary cutaneous melanoma, provide prognostic information and guide management. The Australian Clinical Pract
Externí odkaz:
https://doaj.org/article/1535a3ff7cc2456fbaa9afb9a8445f61
Publikováno v:
Melanoma Management, Vol 6, Iss 3 (2019)
Immune checkpoint inhibitors and BRAF-MEK inhibitors have revolutionized the management and prognosis of patients with metastatic melanoma. However, there is minimal evidence to guide their incorporation into current treatment paradigms for unresecta
Externí odkaz:
https://doaj.org/article/357e87c5dc12403590d14f3b2c479c75
Autor:
David E Gyorki, Jonathan S Zager
Publikováno v:
Melanoma Management, Vol 6, Iss 3 (2019)
Externí odkaz:
https://doaj.org/article/c9551533fae54e7ebe5b8076a84a60cc
Autor:
Jennifer S Downs, David E Gyorki
Publikováno v:
Melanoma Management, Vol 6, Iss 3 (2019)
Management of later stage melanoma has undergone significant changes. Sentinel node biopsy has long been an accepted method of staging, but two recent randomized-controlled trials have provided an evidence base for decision making about completion ly
Externí odkaz:
https://doaj.org/article/e991310058ea4712bab24708cb34a783
Autor:
Katharina Hochheiser, Han Xian Aw Yeang, Teagan Wagner, Candani Tutuka, Andreas Behren, Jason Waithman, Christopher Angel, Paul J Neeson, Thomas Gebhardt, David E Gyorki
Publikováno v:
Clinical & Translational Immunology, Vol 8, Iss 12, Pp n/a-n/a (2019)
Abstract Objective The immune system can halt cancer progression by suppressing outgrowth of clinically occult micrometastases in a state of cancer‐immune equilibrium. Cutaneous melanoma provides a unique opportunity to study the immune contexture
Externí odkaz:
https://doaj.org/article/9388ac1483874e7d93a5c5ce5f8f912b
Publikováno v:
Current Oncology, Vol 30, Iss 7, Pp 5953-5972 (2023)
With the exception of well-differentiated liposarcoma, dedifferentiated liposarcoma, leiomyosarcoma, solitary fibrous tumour, malignant peripheral nerve sheath tumour, and undifferentiated pleomorphic sarcoma, the majority of the ≈70 histologic sub
Externí odkaz:
https://doaj.org/article/4bd5fdbe4acf46e99285ef2b65237777
Autor:
Kristy K, Broman, Tasha M, Hughes, Brooke C, Bredbeck, James, Sun, Dennis, Kirichenko, Michael J, Carr, Avinash, Sharma, Edmund K, Bartlett, Amanda A G, Nijhuis, John F, Thompson, Tina J, Hieken, Lisa, Kottschade, Jennifer, Downs, David E, Gyorki, Emma, Stahlie, Alexander, van Akkooi, David W, Ollila, Kristin, O'shea, Yun, Song, Giorgos, Karakousis, Marc, Moncrieff, Jenny, Nobes, John, Vetto, Dale, Han, Meghan, Hotz, Jeffrey M, Farma, Jeremiah L, Deneve, Martin D, Fleming, Matthew, Perez, Kirsten, Baecher, Michael, Lowe, Roger Olofsson, Bagge, Jan, Mattsson, Ann Y, Lee, Russell S, Berman, Harvey, Chai, Hidde M, Kroon, Juri, Teras, Roland M, Teras, Norma E, Farrow, Georgia M, Beasley, Jane Yuet Ching, Hui, Lukas, Been, Schelto, Kruijff, Brandy, Sinco, Amod A, Sarnaik, Vernon K, Sondak, Jonathan S, Zager, Lesly A, Dossett
Publikováno v:
Annals of Surgery. 277(5):1106-1115
Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Da
Autor:
Carl-Jacob Holmberg, Lars Ny, Tina J. Hieken, Matthew S. Block, Michael J. Carr, Vernon K. Sondak, Christoffer Örtenwall, Dimitrios Katsarelias, Florentia Dimitriou, Alexander M. Menzies, Robyn PM. Saw, Aljosja Rogiers, Richard J. Straker, Giorgos Karakousis, Rona Applewaite, Lalit Pallan, Dale Han, John T. Vetto, David E. Gyorki, Emilia Nan Tie, Maria Grazia Vitale, Paulo A. Ascierto, Reinhard Dummer, Jade Cohen, Jane YC. Hui, Jacob Schachter, Nethanel Asher, H. Helgadottir, Harvey Chai, Hidde Kroon, Brendon Coventry, Luke D. Rothermel, James Sun, Matteo S. Carlino, Zoey Duncan, Kristy Broman, Jeffrey Weber, Ann Y. Lee, Russell S. Berman, Jüri Teras, David W. Ollila, Georgina V. Long, Jonathan S. Zager, Alexander van Akkooi, Roger Olofsson Bagge
Publikováno v:
European Journal of Cancer. 169:210-222
Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease.